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Abstract
The RAS/MAPK signal transduction pathway is an intracellular signaling cascade that transmits environmental signals from
activated receptor tyrosine kinases (RTKs) on the cell surface and other endomembranes to transcription factors in the
nucleus, thereby linking extracellular stimuli to changes in gene expression. Largely as a consequence of its role in
oncogenesis, RAS signaling has been the subject of intense research efforts for many years. More recently, it has been
shown that milder perturbations in Ras signaling during embryogenesis also contribute to the etiology of a group of human
diseases. Here we report the identification and characterization of the first gain-of-function germline mutation in Drosophila
ras1 (ras85D), the Drosophila homolog of human K-ras, N-ras and H-ras. A single amino acid substitution (R68Q) in the highly
conserved switch II region of Ras causes a defective protein with reduced intrinsic GTPase activity, but with normal
sensitivity to GAP stimulation. The ras1
R68Q mutant is homozygous viable but causes various developmental defects
associated with elevated Ras signaling, including cell fate changes and ectopic survival of cells in the nervous system. These
biochemical and functional properties are reminiscent of germline Ras mutants found in patients afflicted with Noonan,
Costello or cardio-facio-cutaneous syndromes. Finally, we used ras1
R68Q to identify novel genes that interact with Ras and
suppress cell death.
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Introduction
Multicellular organisms must extensively coordinate the activ-
ities of many diverse and highly specialized cells, requiring
effective and flexible signaling mechanisms for both development
and tissue homeostasis. Many inter-cellular signals are transmitted
by receptor tyrosine kinases (RTKs), which control key aspects of
cellular growth, differentiation, metabolism and cell death [1,2].
On the other hand, mutations that lead to abnormal activation of
RTKs can generate oncogenes that promote tumorigenesis [3,4].
Ras proteins are guanine nucleotide binding proteins that act as
molecular switches to transduce RTK-signals from the outside to
the interior of the cell [5]. Remarkably, ,20% of all tumors
contain an activating point mutation in Ras [6,7]. Consequently,
this pathway has been extensively studied both in the context of
normal signal transduction, and oncogenic growth. Because the
RTK/RAS signaling network is highly conserved among animals,
genetic model systems have made major contributions for
elucidating this pathway [8,9,10,11].
One major physiologic function of the RTK/RAS pathway
during development is the transmission of anti-apoptotic signals
that suppress the activation of an intrinsic cell death program
[12,13]. In Drosophila, as in mammals, cells are over-produced
during development and compete for limiting amounts of
extracellular survival factors in order to suppress the induction
of apoptosis [14,15]. This strategy permits appropriate matching
of different cell types in a tissue and allows for the elimination of
any superfluous and potentially dangerous cells. A conserved
mechanism for survival signaling involves activation of receptor
tyrosine kinases (RTKs) at the cell surface, which in turn stimulates
the antiapoptotic activity of Ras [13]. Active Ras promotes its anti-
apoptotic effect via several effector pathways, including the
mitogen-activated protein kinase p42/44 (MAPK) of the ERK-
type (extracellular signal-related kinase) via Raf [16,17,18], and
the Akt kinase via Phosphoinositide 3-kinase [19]. In Drosophila,
one major target for the anti-apoptotic activity of Ras is the pro-
apoptotic Hid protein, which is inactivated via phosphorylation by
MAPK [20,21,22]. Active Hid induces apoptosis by binding to
and inhibiting Drosophila Inhibitor of Apoptosis Protein-1 (Diap1),
an essential inhibitor of caspases in Drosophila [23,24,25,26,27]. In
living cells, Diap1 inhibits both initiator and effector caspases, and
its function is required for the survival of virtually all somatic cells
[23,25,26,28,29,30,31]. In response to apoptotic stimuli, Diap1 is
inactivated by natural IAP-antagonists, including Reaper, Hid and
Grim (RHG proteins). The active forms of RHG proteins are
generated in doomed cells by a combination of transcriptional
induction and post-transcriptional regulation [32,33,34,35]. Once
active, RHG proteins form complexes that both disrupt binding of
Diap1 to caspases and also stimulate auto-ubiquitination and
degradation of Diap1, thereby removing the ‘‘brakes on death’’
[27,36]. One important role of Hid is to recruit Reaper to the
outer mitochondrial membrane, which is important for efficient
inactivation Diap1 and apoptosis induction [27]. Survival signals,
such as Spitz in the case of midline glia, inhibit the pro-apoptotic
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23535activity of Hid via activation of EGFR, Ras and MAPK, leading to
direct phosphorylation of Hid by MAPK and inhibition of Hid
pro-apoptotic activity [21,33].
We previously conducted large-scale dominant modifier screens
in Drosophila to identify genetic modifiers of Hid-induced apoptosis
[20]. These screens identified several loss-of-function alleles in
sprouty and gap1, both negative regulators of the RAS/MAPK
signaling pathway and helped define the mechanism by which
MAPK signaling inactivates a critical component of the apoptotic
machinery [22,37]. Here we report the identification and
characterization of another Hid-modifier mutation, which maps
to the switch II region of ras1 (also known as ras85D), the Drosophila
homologue of mammalian N-ras, K-ras and H-ras. Although many
loss-of-function alleles have been described for Drosophila ras1, this
mutation is the first endogenous gain-of-function allele reported
for this gene. We demonstrate biochemically that this viable
hypermorph, ras1
R68Q, produces a defective Ras protein with
reduced intrinsic GTPase activity, but normal sensitivity to GAP
stimulation. These biochemical features are reminiscent of those
recently described for mutant human H-ras and K-ras proteins
known to underlie a group of related developmental disorders that
includes Noonan syndrome, Costello syndrome and cardio-facio-
cutaneous syndrome [38,39,40]. Flies mutant for ras1
R68 exhibit a
number of developmental defects that are characteristic of
abnormally elevated RTK/RAS/MAPK signaling, including
enhanced resistance to apoptosis, supernumerary R7 cells in the
eye and ectopic wing vein formation, demonstrating that the
mutant Ras protein has enhanced signaling capacity in vivo. This
allele should be a useful tool to study the physiological
consequences of modest activation of Ras signaling in vivo. Finally,
we used this mutant to identify novel interactors of Ras that
suppressors cell death.
Materials and Methods
Fly stocks
The following fly stocks were used: GMR-rpr
81 [41], GMR-rpr
34
Cyo/Sco, GMR-hid
1M, GMR-hid
Ala3 and GMR-hid
Ala5 [20], GMR-
hid
10 and hs-hid
3 [24], GMR-grim [42], GMR-phyl [43], GMR-rho
1
[44], vg-GAL4 (F.M. Hoffmann, unpublished), UAS-hid [45], arg
ID7
[46], EGFR
2 = flb
f2 [47], rl
10a [48], sev-ras1
N17 [49], P[slit-1.0-lacZ]
[50], Hml-GAL4, 2xUAS-EGFP (J.A. Rodriguez, unpublished).
Stocks for meiotic recombination mapping (ru
1 h
1 th
1 st
1 cu
1 sr
1 e
s
ca
1 and ru
1 h
1 th
1 st
1 cu
1 sr
1 e
s Pr
1 ca
1/TM6B, Bri
1,T b
1) and stocks for
P-element induced male recombination mapping (y
1 w*; CyO,
H{PDelta2-3}HoP2.1/Bc
1 Egfr
E1 asa source oftransposase and all P-
element insertion lines) were obtained from the Bloomington Stock
Center (Bloomington, IN). All other lines were generated by meiotic
recombination of the appropriate alleles.
Genetic screens
Dominant modifier screens were performed as described in Fig.
S1. Approximately 170,000 F1 progeny from ENU and EMS
mutagenized GMR-rpr
81 flies were screened for modification of a
GMR-rpr
81 induced rough eye phenotype, yielding 25 enhancers
and 5 suppressors (Table S1). Similarly, 300.000 F1 progeny from
ENU, EMS and x-ray mutagenized flies were screened for
suppression of a GMR-hid
10 induced rough eye phenotype,
resulting in the recovery of 128 additional suppressors (Table
S2). In sum total, 158 dominant modifiers of GMR-rpr or GMR-hid
were isolated in these screens.
Complementation analyses using phenotype and map information
placed 133 of these modifiers into 13 complementation groups, while
the remaining mutants represent single hits or have no recessive
phenotype. To further enrich for mutants that are cell death specific,
we eliminated general modulators of GMR promoter expression or
eye development by testing modifiers against GMR-phyl and GMR-rho
induced rough eye phenotypes, which are unrelated to cell death
[43,44]. Inaddition, reasoning that mutantsinvolving apoptosisgenes
should be able to modify cell death phenotypes in contexts other than
the eye, suppressors from the GMR-hid screen were tested for their
ability to suppress hs-hid induced embryonic lethality and vg-GAL4,
UAS-hid induced wing ablation. On the basis of these secondary
screens, we eliminated several complementation groups including
glass, which encodes the transcription factor that drives GMR
expression, Su(GMR)2A and su(GMR)3A, which are known to
indirectly and non-specifically affect GMR promoter expression,
and Su(GMR-hid)3A and Su(GMR-hid)3B, complementation groups
that have not been assigned to a previously characterized gene
[51,52]. We also eliminated 4 alleles linked to the parental GMR-rpr
transgene. Our cell death enriched subset of modifiers therefore
consists of 58 mutants in total, 40 that fall into 6 complementation
groups and 18 single alleles.
All crosses and suppression experiments were carried out at 25uC
except crosses with vg-GAL4 and UAS-hid, which were performed at
both 18uC and 25uC. Suppression experiments with hs-hid were
done by heat shocking 1
st instar larvae at 37uC for 15 minutes.
Biochemistry
A cDNA clone encoding Drosophila ras1 was obtained from the
Drosophila Genomics Resource Center (clone ID: RE53955) and
the entire ras1 ORF was subcloned into pBluescript (Stratagene).
Mutant ras1
R68Q was generated using the QuikChange II XL Site-
Directed Mutagenesis Kit (Stratagene). The Ras ORFs were then
subcloned into pET-28a (Novagen) in frame for an N-terminal His
tag. Catalytic human p120-Gap (GAP-285, amino acids 714–998,
IMAGE Clone: 4829173, Open Biosystems) was subcloned into
the pET41a vector (Novagen) to generate an N-terminal GST tag.
Fusion proteins were expressed in BL21(DE3) E. coli (Invitrogen)
and affinity purified on an AKTA Purifier (Pharmacia) using a
HisTrap FF column (GE Healthcare) for Ras proteins and a
GSTrap FF column (GE Healthcare) for GAP-285. Ras
purification was done according to the procedure described for
human H-Ras [53]. GAP-285 was expressed by inducing cells for
16 hours at 30uC with 0.2 mM IPTG.
Intrinsic GTPase activities were measured using [gam-
ma-
33P]GTP (3000 Ci/mmol, NEN) and the EasyRad Phosphate
Assay (Cytoskeleton) [54]. GAP-stimulated GTPase activities were
measured with a real-time assay using the fluorescent substrate
MDCC-PBP (Invitrogen) and 2 mM Ras protein, with or without,
0.02 mM GAP-285 [55].
Phenotypic Analyses
To visualize larval hemocytes, wandering 3
rd instar larva
expressing UAS-EGFP driven by Hml-GAL4 were collected and
immobilized on ice prior to imaging [56]. MG cells in stage 17
embryos were visualized using P[slit-1.0-lacZ] and ß-gal immuno-
histochemistry as previously described [57]. The number of MG
was averaged for segments T2 to A5. Tangential sections (1 mm) of
adult eyes were prepared according to standard protocols for
analysis of ommatidia [58].
Results
Genetic screens for dominant modifiers of apoptosis in
Drosophila
Dominant modifier screens are designed to detect pathway
components for which small perturbations in gene dosage can alter
A Germline Hypermorph in Drosophila ras1
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of-function and gain-of-function mutations. We used eye-specific
expression of the Drosophila cell death genes hid or rpr under control
of the GMR promoter to generate a dosage sensitive eye ablation
phenotype and then screened for dominant modifiers of this
phenotype to identify regulatory components of the intrinsic cell
death program [20,24,41]. Although several genes identified in
this way have been reported, details of these screens have not been
previously published and are provided in the supplementary
material (Fig. S1, Tables S1 and S2).
We identified a subset of 58 mutants that specifically affect rpr or
hid-induced cell death. 40 of these correspond to 6 complemen-
tation groups, while 18 represent single alleles. Of the 6
complementation groups identified, 3 correspond to genes that
regulate EGF receptor (EGFR) signaling. Five loss-of-function
alleles each of gap1 and sprouty, both negative regulators of EGFR/
MAPK signaling, were recovered as strong, hid specific suppres-
sors. These mutants have been characterized elsewhere [20]. We
also isolated five loss-of-function Star alleles as enhancers of GMR-
rpr. Star is required for the correct processing of Spitz, a stimulatory
ligand of EGFR [59]. Ten alleles of diap1, the major biochemical
target for the pro-apoptotic activity of RHG proteins were
isolated, including loss-of-function alleles that enhance rpr-, hid-
and grim-induced cell death and two distinct classes of gain-of-
function alleles [23,28,31]. The fifth complementation group,
consisting of 12 alleles, displayed a differential modulation of cell
death phenotypes reminiscent of diap1 RING mutants and was
found to encode dbruce, the Drosophila ortholog of mouse Bruce and
human Apollon [60,61]. This very large (4852 amino acid) BIR-
containing protein is cytoprotective against caspases and required
for spermatid survival [62,63,64]. Finally, 5 single alleles from the
GMR-rpr screen likely represent weak hypomorphs of diap1 as they
map close to the diap1 locus, and a sixth allele was identified as an
allele of Delta.
The remaining complementation group, Su(GMR-hid)2A, and
12 additional single alleles were previously not characterized. We
chose one allele, Su(21-3s) for further analysis based on its ability
to potently suppress hid-induced phenotypes (eye/wing/organis-
mal lethality) without non-specifically affecting GMR-phyl (Table
S2). Su(21-3s) mutants are homozygous viable and do not have
overt abnormalities. This mutant was mapped by meiotic
recombination to the right arm of chromosome 3, near the visible
marker curled.
Characterization of Su(21-3s) suppressor phenotypes
We first examined more rigorously the suppression phenotypes
of Su(21-3s) in the eye by testing the modifier effects of one or two
copies of Su(21-3s) against various GMR expression constructs.
This analysis confirmed that Su(21-3s) potently suppresses GMR-
hid induced cell death in a dosage dependent manner (Fig. 1A,B).
We found suppression of GMR-rpr and GMR-grim phenotypes,
however, to be extremely weak, even with two copies of Su(21-3s)
(Fig. 1E,F). Given that hid is highly expressed in the developing
eye, we believe the small effect exerted by Su(21-3s) on GMR-rpr
and GMR-grim is due primarily to a suppression of endogenous Hid
activity and not that of Rpr or Grim [24]. We conclude from these
data that Su(21-3s) is a specific suppressor of hid induced cell death.
The activity of Hid is regulated by the EGFR/MAPK pathway
in a manner that depends on intact MAPK phosphorylation sites
in Hid. Our analysis here reveals that Su(21-3s) readily suppresses
GMR-hid
Ala3,ahid allele lacking 3 of 5 predicted MAPK
phosphorylation sites, but fails to suppress GMR-hid
Ala5, which is
missing all 5 MAPK sites (Fig. 1C,D) [37]. This requirement for
one or two of the predicted MAPK phosphorylation sites in Hid
(Ser-121 and Thr-228), along with the observed specificity for
GMR-hid suppression, strongly suggested that Su(21-3s) might be
mediating its suppressive effects through the EGFR/MAPK
pathway.
We further extended analysis of the Su(21-3s) suppression
phenotypes to the developmental context of larval hemocytes, an
important model system for the study of vertebrate haematopoiesis
[65,66]. Drosophila hemocytes require trophic signaling from
multiple pathways for their survival and in its absence undergo
caspase dependent cell death [67,68]. Larval hemocytes also
undergo caspase dependent cell death in response to ectopic hid
expression [69]. Using a hemocyte specific promoter to drive
expression of UAS-EGFP, we are readily able to visualize
hemocytes in wandering 3
rd instar larvae (Fig. 1G) [56].
Ectopically expressing UAS-hid using the same driver results in
near complete ablation of hemocytes by the 1
st instar larval stage
(data not shown) and generates 3
rd instar larvae that are
completely devoid of hemocytes (Fig. 1H). We found that the
Su(21-3s) mutation is able to partially suppress this cell death such
that EGFP expressing hemocytes are clearly visible anteriorly in
the lymph glands of 3
rd instar larvae (Fig. 1I). Circulating
hemocytes, however, appear to remain susceptible to hid-induced
cell death and are missing, even in the presence of two copies of
the Su(21-3s) allele. It may be that Su(21-3s) is a weak suppressor
of cell death in hemocytes, sufficient to suppress Hid activity in
young hemocytes localized to the supportive environment of a
lymph gland, but insufficient in the context of a mature circulating
hemocyte.
Su(21-3s) is a viable gain-of-function allele of ras1
(ras85D)
In order to identify the gene responsible for the Su(21-3s)
phenotype, we mapped it by a second, finer round of meiotic
recombination to a 1 Mb interval between 85A and 85E, then
further localized the mutation by P-element mediated male
recombination to a 270 Kb interval between 85D11 and 85E1
(Fig. 2A). Given that Su(21-3s) differentially suppresses hid, but not
grim or rpr in a manner reminiscent of EGFR/MAPK pathway
mutants, we suspected that Su(21-3s) might be a rare hypermor-
phic allele of ras1, or ras85D as it is otherwise known, because it is
located within this interval. Indeed, when we sequenced ras1 in a
candidate gene approach, a G to A transition in exon3 was
identified. This mutation results in an amino acid substitution at
position 68 of the Ras protein, replacing a positively charged
arginine within the universally conserved switch II region of Ras
with a neutral glutamine (Fig. 3).
The switch regions of Ras have been defined as regions that
undergo a large conformational change when Ras transitions from
the GTP- to the GDP-bound state [70]. Detailed biochemical
analysis and crystal structures have revealed that residues in the
switch II region of Ras contact and are stabilized by the GTPase
Activating Protein (GAP), allowing them to participate up to a
1000 times more efficiently in the catalysis of GTP [71]. As a
consequence, mutations in the switch II region of Ras interfere
with its catalytic GTPase activity and prolong the time Ras
remains bound to GTP. Mutations that reduce the GTPase
activity of Ras are hypermorphic since it is the GTP-bound form
of Ras that engages and activates downstream signaling effectors.
The signaling activities of Ras are terminated when GTP bound
by Ras is converted to GDP, explaining why the most frequently
occurring oncogenic mutations in Ras, at amino acids 12,13 and
61, also render Ras biochemically inert as a GTPase (Fig. 3)
[72,73]. It seemed feasible, therefore, that the R68Q mutation
identified in Su(21-3s) flies could similarly result in a Ras protein
A Germline Hypermorph in Drosophila ras1
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MAPK signal that suppresses cell death induced by GMR-hid.
We reasoned that if the Su(21-3s) phenotype is due to a gain-of-
function mutation in ras1, it should be revertible by introduction of a
second, intragenic loss-of-function mutation. To test this, we
conducted a reversion screen for loss of the Su(21-3s) suppression
phenotype and successfully recovered two mutants containing
intragenic loss-of-function ras1 mutations (Figs. 2 and S1). One
revertant contains a 31 bp deletion in ras1 t h a tr e s u lt si naR a sp r o t e i n
truncated at amino acid 87. The second revertant contains an in
frame 18 bp deletion of ras1 that removes amino acids 87–92 which
are essential for Ras function [74]. These revertants have genetic
Figure 1. Suppression phenotypes of Su(21-3s). GMR-hid but not GMR-grim or GMR-rpr induced cell death is dominantly suppressed by Su(21-3s)
in a manner that requires intact MAPK phosphorylation sites in the overexpressed Hid protein. (A–F) The resulting rough eye phenotype is strongly
suppressed in a dosage dependent manner by one (’) or two (0) copies of the Su(21-3s) mutation when induced by overexpression of either a weak,
GMR-hid
1M (A) or a strong, GMR-hid
10 (B) allele of GMR-hid, but is only weakly attenuated by Su(21-3s) when induced by GMR-grim (E) or GMR-rpr (F). In
addition, Su(21-3s) suppresses cell death induced by overexpression of a Hid protein lacking 3 of 5 predicted MAPK phosphorylation sites, GMR-hid
Ala3
(C) but not by GMR-hid
Ala5 (D), a hid allele lacking all 5 MAPK consensus sites (Bergmann, et al. 1998). (G-I) Death of larval hemocytes induced by
overexpression of Hid under control of the hemocyte specific driver Hml is also partially suppressed by the Su(21-3s) mutation. (G) EGFP is used to
visualize hemocytes in wildtype 3
rd instar larva: Hml-GAL4,2 x UAS-EGFP. (H) Overexpression of Hid in hemocytes results in their complete ablation by
the 1
st instar larval stage: Hml-Gal4,2 x UAS-EGFP; UAS-hid. (I) Su(21-3s) is able to partially suppress hemocyte death induced by Hid. Surviving
hemocytes appear to be concentrated within the lymph glands as shown in the inset: Hml-Gal4,2 x UAS-EGFP; UAS-hid, Su(21-3s).
doi:10.1371/journal.pone.0023535.g001
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alleles ras1
e1B and ras1
e2F and supporting the idea that the Su(21-3s)
phenotype is due to a revertible gain-of-function mutation in ras1.
As an allele of ras1, Su(21-3s) should interact genetically with
other members of the MAPK signaling pathway in a predictable
manner. We crossed GMR-hid
10 flies in a Su(21-3s) background to
mutants of MAPK signaling and observed the degree of cell death
in the eye (Fig. S2). MAPK signaling mutants tested include argos,
ras1, rolled and EGFR. In this analysis, we found that the Su(21-3s)
mutant behaves in a manner consistent with that expected for a
gain-of-function ras1 allele. For example, Su(21-3s) is not much
affected by loss-of-function mutations in upstream components of
MAPK signaling, such as argos or EGFR but is strongly ameliorated
by loss of downstream components, such as rolled. Additionally,
when a dominant negative form of Ras1 (sev-ras1
N17) is expressed
in the eye, the suppressive effects of Su(21-3s) are completely
abrogated. On the basis of our mapping data, the reversion screen,
the sequence data and the genetic interaction data presented
above, we conclude that Su(21-3s) is a hypermorphic allele of ras1,
which we rename here, ras1
R68Q.
Biochemical analysis of recombinant Ras1
R68Q protein
To test the hypothesis that exchanging a positively charged
arginine with a neutral glutamine at position 68 of Ras results in a
protein with deficient GTPase activity, the intrinsic GTPase rates
of wildtype and mutant Drosophila Ras1 proteins were measured.
Full-length wildtype Ras1 and mutant Ras1
R68Q were bacterially
expressed and purified as His-tagged fusion proteins, yielding large
amounts of pure, catalytically active enzyme. Intrinsic GTPase
activity rates were measured with a kinetic phosphate assay
employing [camma-
33P]GTP as substrate. This sensitive assay
revealed that Ras1
R68Q has an intrinsic GTPase activity that is
approximately 1/3 that of wildtype Ras1, with enzymatic rates
(kcat) of 0.020 min
21 and 0.063 min
21, respectively (Fig. 4C). Since
many activating Ras mutations also result in an enzyme that is
insensitive to GTPase activating proteins (GAPs), the ability of
Ras1
R68Q to be stimulated by GAP was also assessed. Recombi-
nant human GAP-285 protein was purified by affinity chroma-
tography and its ability to stimulate wildtype and mutant Ras1
proteins was tested using a real-time fluorescent assay. These
experimental data show that Ras1
R68Q remains amenable to GAP
stimulation (Fig. 4D). This means that in contrast to constitutively
active Ras mutants such as oncogenic Ras
V12, whose GTPase
activity is completely refractory to stimulation by GAPs, Ras1
R68Q
can be regulated and is able to cycle between on and off states
[75]. Together, these biochemical data support the hypothesis that
Ras1
R68Q has a reduced basal level of GTPase activity, remains in
its active GTP-bound form for longer and thus has an enhanced
Figure 2. Su(21-3s) is a gain of function allele of ras1 (ras85D), the Drosophila homolog of human n-ras, h-ras and k-ras. (A) The cell death
suppression phenotype of Su(21-3s) mutants was localized by meiotic recombination to the right arm of the 3rd chromosome as indicated by the
large horizontal arrow. P-element induced male recombination mapping further localized this suppressor to the region depicted by the short arrow.
An enlargement of this interval (5.162-5.452 Mb on the physical map) is shown below, illustrating the ORFs contained therein. The ras85D (ras1) locus,
outlined with a red box, was sequenced in a candidate gene approach and a G to A transition in exon3 (G641A) was identified. (B,C) A screen for
reversion of the dominant Su(21-3s) suppressor phenotype generated a number of genetic revertants, two of which, Su(21-3s)
R11 and Su(21-3s)
41, were
molecularly determined to be intragenic loss of function ras1 alleles. (B) A schematic of the ras1 locus, with exons boxed and coding regions stippled,
illustrates the Su(21-3s) point mutation in exon 3 (G641A) and the small intragenic deletions identified in Su(21-3s)
R11 and Su(21-3s)
R41 (labeled R11
and R41 respectively, with deleted sequences underlined in black.) The red arrows correspond to primers used in a PCR diagnostic (below) used to
confirm that both revertants contain the original G641A mutation. (C) Sequence analysis of these lethal revertants using strand specific PCR revealed
that Su(21-3s)
R11 contains an 18bp deletion that removes essential amino acids 87–92 from the Ras1 protein. Su(21-3s)
R41 was found to have a 31bp
deletion, resulting in a frameshift that generates a truncated Ras1 protein.
doi:10.1371/journal.pone.0023535.g002
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compatible with nearly normal cellular function and organismal
development. These biochemical features are highly reminiscent of
those recently described for germline H-ras and K-ras mutants
found in the developmental disorders Noonan syndrome, Costello
syndrome and cardio-facio-cutaneous syndrome [38,40].
Ras1
R68Q promotes survival of midline glia (MG)
The survival of Drosophila midline glia (MG) cells during
embryonic development depends on survival signals mediated by
the EGFR/Ras/MAPK pathway [21,76]. During formation of the
Drosophila central nervous system, there are initially approximately
ten MG cells per segment at stage 13. Most of these undergo
apoptosis in a RHG-dependent manner such that by stage 17, only
three MG per segment survive [45,77]. We tested the effect of
ras1
R68Q in this system. MG cells were visualized in wildtype and
ras1
R68Q embryos using the MG-specific pslit-lacZ reporter, and
marked MG cells were carefully counted. This analysis revealed an
increase in the number of MG cells in ras1
R68Q embryos as
compared to wildtype embryos (Fig. 5E,F). Stage 17 wildtype
embryos contained an average of 2.8 MG cells per segment
(n=448) whereas ras1
R68Q embryos contained an average of
3.3 MG cells per segment (n=420). This difference is statistically
significant by an unpaired t-test (p95#0.0001) and is consistent
with an increase of Ras activity in ras1
R68Q flies (Fig. 5G).
Ras1
R68Q causes supernumerary R7 cells in the eye
The adult Drosophila eye comprises about 800 ommatidia,
each with a precise, reproducible structure consisting of eight
photoreceptors and 12 accessory cells [78,79]. Adoption of a
neuronal cell fate by the precursor of the R7 photoreceptor
requires an inductive signal from the neighboring R8 cell and is
dependent on EGFR/MAPK signaling [80,81,82]. Further-
more, the cone cell precursors are capable of acquiring an R7
cell fate if MAPK signaling is ectopically activated in these cells,
resulting in extra R7 cells that are easily visualized [83]. To
determine if the ras1
R68Q mutation exerts effects in a paradigm
other than apoptosis, semi-thin plastic sections of adult eyes
were prepared and analyzed for defects in ommatidia formation.
We observed two types of defect in ras1
R68Q flies typical for
mutations that increase RAS/MAPK signaling during eye
development. First, we detected ommatidia with supernumery
R7 cells (Fig. 5B,C). Second, we noticed occasional ommatidia
missing outer photoreceptor cells, also a phenotypic conse-
quence of elevated MAPK signaling (Fig. 5D) [83]. The
developmental defects in retinal cell differentiation observed
here further supports our hypothesis that ras1
R68Q is a gain-of-
function ras1 allele.
The wings of ras1
R68Q flies contain ectopic vein material
In addition to defects in the eye and midline glial cells, ras1
R68Q
flies also show abnormalities in adult wing tissues. Homozygous
ras1
R68Q flies have an extra longitudinal ‘‘veinlet’’ branching off the
posterior crossvein (Fig. 5I). Additionally, an ectopic longitudinal
vein was seen beneath the posterior crossvein and an ectopic
crossvein appeared between the L4 and L5 wing veins near the
hinge. These defects are remarkably similar to those observed in
the wings of rl
sem and DER
Ellipse flies, which have elevated levels of
MAPK signaling [84]. When UAS-ras1
R68Q was overexpressed in
the wing using en-Gal4, extensive ectopic wing vein material and
blisters developed (Fig. S3). Overexpression of wildtype Ras1 gave
a similar but less severe phenotype. Finally, we attempted to
express ras1
V12 in the wing using en-Gal4 but found this to cause
organismal lethality.
Figure 3. Amino acid alignment of fly, worm and mammalian Ras1. These homologs have extensive primary sequence homology. Drosophila
Ras1 (dmRas1), for example, is 87% identical to human K-ras (hsKras) at the amino acid level when C-terminal membrane-targeting sequences are
excluded. Conserved regions are shaded in grey, with residues identical to the consensus sequence represented by a grey dot, while non-conserved
residues remain unshaded. Five highly conserved signature motifs named ‘‘G box’’ sequences, labeled G1-G5 and boxed in red, are found in all
families of small GTPases. Secondary structural elements are depicted as rectangles below the primary sequence alignment (alpha-helices, a1-a5, are
dark grey and ß-sheets, ß1–ß6, light grey) and the phosphate-binding loop (P-loop), which binds the camma-phosphate of GTP, and the nucleotide-
sensitive switchI and II regions are indicated. The Switch regions are known to undergo large conformational changes upon exchange of bound GDP
for GTP. The mutational spectrum of Ras is illustrated above the alignment, showing the distribution of amino acid substitutions encoded by
germline mutations found for the developmental disorders Noonan, Costello and CFC syndromes and the most frequent cancer-associated somatic
mutations (labeled in red). R68Q indicates the mutation characterized in this study, a non-conserved arginine to glutamine amino acid substitution
within the switch II region of Drosophila Ras1 (dashed red box). hs, H. sapiens; dm, D. melanogaster; mm, M. musculus; ce, C. elegans.
doi:10.1371/journal.pone.0023535.g003
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R68Q in the eye induces both
severe overgrowth and cell death
It was previously shown that overexpression of wildtype Ras1 in
the Drosophila eye, even at the high levels obtained by transgene
expression, results in little or no observable phenotypic effect [83].
For this reason, studies of elevated Ras signaling in Drosophila
regularly rely on a very strong, constitutively active Ras
V12 mutant
allele. We similarly observed that wild-type UAS-ras1 expressed by
GMR-Gal4 had little effect on eye development in 11 independent
transgenic lines (Fig. S4). In striking contrast, seven independent
transgenic lines expressing UAS-ras1
R68Q resulted in highly distorted
eyes that exhibited both hyperplastic tissue overgrowth and
widespread cell death ablation phenotypes. For purposes of
comparison, we attempted to express two different UAS-ras1
V12
alleles in the same manner, but again found this induced organismal
lethality (likely due to the fact that GMR drives some expression in
tissuesotherthan the eyeandRas1
V12inducesnon-cellautonomous
cell deathwhenoverexpressed)[85].Wegeneratedmanymore than
seven UAS-ras1
R68Q transgenic lines but similarly found many of
them to be lethal in combination with GMR-Gal4. This lethality was
not observed in any of the 16 independent UAS-ras1 transgenic lines
tested. These experiments further support the view that Ras1
R68Q is
an activated form of Ras that nevertheless remains amenable to
regulation and therefore is less biologically potent than the
constitutively active Ras1
V12 protein.
Identification of Novel Ras Interactors and Suppressors of
Cell Death
In the reversion screen described above we were also able to
recover additional suppressors of GMR-hid. We collected a number
Figure 4. Structural and biochemical analysis of wildtype and mutant Ras1. (A–B) Three-dimensional crystal structure of human H-Ras (pink)
boundtotheGTPase-activatingdomainofhumanGTPase-activatingproteinp120
GAP(GAP-334,blue)inthepresenceofaluminumfluoride(AlF3,green.)
The positions of oncogenic residues glycine-12 (G12) and glutamine-61 (Q61) as well as the mutant residue in ras1
R68Q flies, arginine-68 (R68), areshown
inyellow.TheSwitchIIregionofRas,ofwhichQ61andR68areapart,isstabilizedbyGAP-334.(B)Anenlargementof(A)showingthefingerloopofGAP-
334, which supplies an arginine side chain (arginine-789) into the active site of Ras to neutralize developing charges in the transition state (Scheffzek
et al., 1997). R68, located proximally to the catalytic site of Ras, also extends a positively charged guanidinium group towards the active site. The images
were constructed using the Entrez software Cn3D with mmdbId:51925 (Chen et al., 2003). Guanosine diphosphate (GDP,brown); Mg
2+ (grey). (C) The
intrinsic GTPase activities of affinity purified drosophila Ras1
wt (blue) and Ras1
R68Q (black) were determined using a kinetic phosphate assay employing
[camma-
33P]GTP as a substrate. The conditions of the assay are such that the reaction proceeds with unimolecular kinetics and is insensitive to the
amount of Ras protein employed (dashed vs. undashed lines). The mutant Ras1
R68Q has an intrinsic GTPase activity that is approximately 1/3 that of
wildtype Ras1 (kcat=0.020 min
21 and 0.063 min
21 respectively.) (D) Human GAP-285 protein was purified by affinity chromatography and its ability to
stimulate wildtype and mutant Drosophila Ras1 proteins was tested using a real-time fluorescent assay. Both wildtype and mutant Ras1 proteins are
sensitive to GAP stimulation (dashed vs. undashed lines). Data is the average of three independent experiments. Error bars are in red.
doi:10.1371/journal.pone.0023535.g004
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mapped them using deletions on the 3
rd chromosome. As
indicated in Table 1, we successfully recovered 14 suppressors
that fall into 8 complementation groups. In most cases, we were
able to identify a single gene that appears to be responsible for the
suppressors phenotype (indicated in bold). In two cases, the
mutations were narrowed to a small region, but we were unable to
unequivocally identify a single candidate. We also recovered
mutations in the glass gene, which affects expression from the
GMR-driver [86]. We recovered mutations in Gap1 and Delta,
both of which were identified in our original hid suppressor screen,
indicating an overlap in the mutational spectrum between the two
screens [20]. Based on previous reports, mutations in Gap1 are
expected to suppress GMR-hid, and Delta/Notch signaling is
known to intersect and cooperate with the Ras/Mapk pathway
[87]. Interestingly, we also isolated a number of novel ras
interactors, including four alleles of the predicted transcription
elongation factor Su(Tpl) and an allele of notum, a component of
the Wnt/Wingless signaling pathway. These results indicate that
use of the ras
R68Q allele in screens may indeed uncover novel
regulatory interactions that have been missed with other strategies,
including those that make use of the constitutively active, non-
regulatable ras
V12 hypermorph.
Discussion
We have conductedgenetic screensfor dominant modifiers of cell
death induced by the Drosophila IAP-antagonists, hid and rpr. From
Figure 5. Ras1
R68Q mutants exhibit several developmental defects characteristic of elevated Ras/MAPK signaling. (A–D) Semi-thin
plastic sections of adult eyes were prepared and analyzed for defects in ommatidia formation. (A) Wildtype ommatidia are precisely ordered,
containing one R7 cell and six outer photoreceptor cells. (B–D) Ras1
R68Q ommatidia show two defects typical of mutations that increase Ras/MAPK
signaling during eye development; supernumery R7 cells (arrows, B,C) and mislocalized (red circle, C) or missing (red circle, D) outer photoreceptor
cells. The schematic illustrates the major cell types present in ommatidia. (E-G) Midline glial (MG) cells were visualized in wildtype (E) and ras1
R68Q (F)
stage 17 embryos using the MG-specific reporter construct P[slit-1.0-lacZ]. During development, the majority of MG undergo apoptosis such that at
this stage only about three MG per segment normally survive. Elevated Ras/MAPK signaling allows for increased survival of MG cells and is reflected
by an increase in the number of persisting MG cells per segment (arrows and inset, F). (G) Wildtype embryos contain an average of 2.8 MG cells per
segment (n=448) whereas ras1
R68Q embryos contain an average of 3.3 MG cells per segment (n=420). This difference is statistically significant by an
unpaired t-test (p95#0.0001). (H,I) Flies bearing the ras1
R68Q allele develop ectopic wing material including extra longitudinal ‘veinlets’ near the
posterior crossvein and an extra crossvein near the wing hinge (arrows, I) The area boxed in red is shown magnified below. PCV, posterior crossvein;
ACV, anterior crossvein; L5, L5 wing vein.
doi:10.1371/journal.pone.0023535.g005
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identify 58 cell death specific modifiers. Of these, 40 alleles were
placedinto sixcomplementationgroupsthat definebothknownand
unknown genes. These include Star, gap and sprouty involved in
EGFR/MAPK signaling, the known cell death regulator diap1, the
very large BIR and UBC containing dbruce, and an unknown gene,
Su(GMRhid)2A that remains unidentified. Here we focused on a
previously uncharacterized cell death suppressor originally termed
Su(21-3s). Using a combination of meiotic and P-element induced
male recombination, genetic reversion, biochemistry and in vivo
analysis, we demonstrate that this mutant is a gain-of-function
mutation in ras1 (ras85D), the Drosophila homolog of human K-ras, N-
ras and H-ras. We also show that this allele affects cell fate decisions
and the pattern of normal, developmental apoptosis in paradigms
known to depend on Ras-signaling.
One important role of Ras signaling during development is the
transmission of an anti-apoptotic signal [13,20,22]. As previously
reported, the pro-apoptotic protein Hid contains 5 potential
MAPK phosphorylation sites that are essential for its sensitivity to
Ras-mediated inhibition [20]. A Hid protein with either 3/5 or 5/
5 mutant MAPK sites (Hid
Ala3 and Hid
Ala5, respectively) was
refractory to suppression by the gain-of-function MAPK allele rl
Sem
(a very mild suppression by rl
Sem is due to phosphorylation of the
endogenous wildype Hid protein). In contrast, there was still some
suppression of Hid
Ala3 and Hid
Ala5 by RasV12. It was postulated
that this might be due to the ability of Ras, unlike MAPK, to exert
additional anti-apoptotic effects through activation of the PI3-K/
Akt-kinase effector branch. In the current study, we found that
ras
R68Q was able to partially suppress Hid
Ala3 but not Hid
Ala5
(Fig. 1C,D). Because Hid
Ala3 retains two phosphorylation sites, it
appears that partial phosphorylation of Hid is sufficient for a mild
inhibitory effect, and that all five phospho-acceptor sites need to be
eliminated in order for Hid to become refractory to inhibition by
MAPK. Furthermore, it appears that Ras
R68Q, unlike Ras
V12,i s
unable to exert an additional suppressive effect via PI3-K/Akt-
kinase. Perhaps the enhanced signaling activity of Ras
R68Q is able
to activate the MAPK effector branch, but does not reach a
required threshold to engage the PI3-K/Akt-kinase pathway
[59,88,89,90,91]. This may also help to explain the organismal
viability of Ras
R68Q as compared to Ras
V12. Along the same line,
Ras
R68Q was able to suppress Hid-induced cell death of
lymphocytes within the protective environs of the lymph gland
but not of those that were circulating (Fig. 1G-I). In sharp contrast,
over-expression of Ras
v12 in hemocytes not only leads to survival
of circulating hemocytes but in fact results in a massive
overproliferation of hemocytes (Rodriguez and Steller, unpubl.
data) These results serve to highlight the exquisite sensitivity of
biological systems to the degree of Ras signaling and suggest that
between the extremes of wildtype Ras and constitutively active
Ras
V12 lies a large spectrum of biological responsiveness.
Ras is highly conserved among metazoans and a number of Ras
structures have been published that make it possible predict how
mutations in specific regions might affect function. In the case of
Ras
R68Q, we considered that this change may affect the transition
state of Ras. According to the ‘‘arginine-finger hypothesis’’
proposed by Scheffzek and colleagues, GTPase-activating-proteins
(GAPs) dramatically accelerate the GTPase reaction of Ras by
supplying an arginine side chain (arginine-789 in the case of GAP-
334) into the active site of Ras to neutralize developing charges in
the transition state [71]. A detailed analysis of the interactions
between Ras and GAP-334 showed no role for R68 of Ras,
explaining why Ras
R68Q can be stimulated by GAP [71,74,92,93].
However, a close inspection of the Ras catalytic site (Fig. 4B) shows
that R68 extends its side chain towards the catalytic center [94].
Mutating R68 to glutamine removes a stabilizing positive charge
from the transition state and, according to the arginine-finger
hypothesis, would be expected to result in less efficient hydrolysis
of GTP. We tested this prediction biochemically and indeed found
that Ras
R68Q hydrolyzes GTP intrinsically at a reduced rate,
approximately 30% of that of wild type GTP (Fig. 4C.)
Oncogenic mutations in Ras occur most frequently at codons 12,13
or 61 and result in an enzyme with deficient GTPase activity. This
renders Ras inactive because Ras is ‘on’ when bound to GTP and
switches ‘off’ by hydrolyzing bound GTP to GDP. Inhibition of Ras
GTPase activity therefore stabilizes Ras in its active conformation,
prolonging its recruitment and activation of downstream signaling
components [5,7,10,70,95]. The reduced GTPase activity of Ras
R68Q
means that it would remain in its active GTP-bound conformation for
longer periods of time allowing for enhanced signaling to downstream
effector pathways. As noted above, however, Ras
R68Q may not remain
in an active state sufficiently long to engage the catalytic p110 subunit
of PI3K. An interesting alternative possibility however may be that
R68 is directly involved in an interaction with PI3K and a mutation in
R68 negatively affects this interaction. This raises the intriguing
possibility that some of the phenotypes described for Ras
R68Q (Fig. 5)
may actually be due to a loss, rather than a gain of PI3K activity.
During the initial mapping and characterization of ras1
R68Q,w e
conducted a reversion screen in order to provide genetic evidence
for our hypothesis that we had identified a rare gain-of-function
allele in ras85D (Fig. 2). While searching for revertants, we also
recovered several mutants that were strong suppressors of GMR-
hid. Recognizing that these mutants might be synergizing with
ras1
R68Q to produce such a strong suppression, we successfully
recovered and mapped 14 of these suppressors. As indicated in
Table 1, most were mapped to a single candidate gene. Since these
mutants were essentially derived from a dominant modifier screen
for suppression of GMR-hid induced cell death, but within a
sensitized ras1
R68Q background, we expected the mutational
spectrum to be overlapping, yet distinct from that of previous
GMR-hid or UAS-Ras
V12 based screens. Indeed several suppressors
turned out to overlap with ones identified previous screens.
However, we also isolated two novel interactors: one allele of notum
and four alleles of Su(Tpl). This demonstrates the utility of ras1
R68Q
to identify novel genetic interactions. While notum affects the Wnt/
Wingless signaling pathway, Su(Tpl) is thought to function in the
regulation of transcription in response to stress [96,97,98].
Table 1. Suppressors of GMR-hid recovered from the
reversion screen.
Complementation Group Location Candidate Gene
SupX3/SupX6 67C10 Gap1
SupE6.1/SupE6.2 66E6-67B1 Argk?
SupE8.1/SupE8.2 66B6-66C1 ERR?
SupX9/SupE10.1/SupE10.2/SupX13 76D3 Su(Tpl)
SupX8 72C3 notum
SupE7.2 99E4 hdc
rasR68Q interactor1 62B1 drpr
rasR68Q interactor2 92A1 Dl
In most cases, a single mutant gene corresponding to these suppressors could
be identified (indicated in bold). In two cases, the mutations were narrowed to
a small region but a single gene could not be unequivocally identified; in these
cases, we list the most likely candidate gene (with an ‘‘?’’) based on mapping
data and published literature.
doi:10.1371/journal.pone.0023535.t001
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from a combination of biochemical experiments conducted in
mammalian tissue culture, and genetic studies in model organisms
[10]. For example, Ras-mediated signaling regulates the specifi-
cation and differentiation of R7 photoreceptors in the Drosophila
eye [80,81,99]. However, until now, studies on the physiological
consequences of elevated Ras in Drosophila have relied on
overexpression of the activated ras1
v12 allele [83,85,100]. The
viable hypermorphic ras1 allele described here, ras1
R68Q, represents
the first endogenous gain-of-function mutation in Drosophila Ras
and hence offers a new tool for the analysis of Ras biology in situ.
In particular, certain aspects of Ras biology have remained largely
inaccessible to the use of constitutively active versions of this
protein. This is because mutants, such as ras1
v12, do not cycle
normally between off and on states, are insensitive to regulatory
circuits and are generally not compatible with organismal
development. As a consequence, in certain paradigms and
contexts, ras1
v12 actually behaves as a loss-of-function mutant
rather than a hypermorph, occluding the biological interpretation
of Ras function in vivo [101]. Therefore, the use of milder, viable
hypermorphs of Ras, such as ras1
R68Q, offers the potential for a
refined understanding of the normal physiological roles of this
important protein. Significantly, the ras1
R68Q allele described here
shares overall biochemical properties with recently discovered
mutations in k-ras and h-ras that underlie human developmental
disorders, such as Noonan, Costello and CFC syndromes.
Supporting Information
Figure S1 Genetic schemes for dominant modifier and
reversion screens. (A) GMR-rpr screen. yw; GMR-rpr
81 homozy-
gous males were fed a solution of sucrose and 0.25mg/ml ENU or
25 mM EMS and mated to females of the same strain. F1 progeny
were screened for suppression or enhancement of the parental
rough eye phenotype. Of the 170,000 F1 progeny screened, ,95%
derived from ENU treated males, while 5% were from EMS treated
males (B) GMR-hid screen. yw males were treated as above or with
4500 rad x-rays and then crossed to GMR-hid
10 homozygous
females. F1 progeny were screened for suppression of the GMR-
hid
10 rough eye phenotype. Of the 300,000 F1 progeny screened,
,49% derived from EMS treated males, ,49% from x-ray treated
males and 2% from ENU treated males. (C) Reversion screen.
HomozygousSu(21-3s) males weretreatedwith4000 rad x-rays and
crossed to GMR-hid
1M; Sb/TM6B females. 80,000 F1 progeny were
screened for loss of the Su(21-3s) suppression phenotype.
(TIF)
Figure S2 The Su(21-3s) mutant differentially interacts
with components of the EGFR/MAPK pathway. Suppres-
sion of the GMR-hid10 induced eye ablation phenotype by Su(21-
3s) (A vs D) is not much affected by loss of function mutations in
upstream components of MAPK signaling such as egfr (E) or argos
(F), but is strongly ameliorated by loss of downstream components,
such as rolled (B). Additionally, when a dominant negative form of
Ras1 (sev-ras1
N17) is expressed in the eye, the suppressive effects of
Su(21-3s) are completely abrogated (C). Genotypes: (A) GMR-
hid
10/+, (B) GMR-hid
10/rl
10A;Su(21-3s)/+, (C) GMR-hid
10/+;Su(21-
3s)/sev-ras1
N17, (D) GMR-hid
10/+;Su(21-3s)/+, (E) GMR-hid
10/
egfr
2;Su(21-3s)/+, (F) GMR-hid
10/+;Su(21-3s)/arg
lD7.
(TIF)
Figure S3 Overexpression of ras1 in the wing induces
ectopic vein material. Overexpression ofeitherwildtype ras1 (C)
or mutant ras1
R68Q (D) using the en-Gal4 driver results in the
deposition of significant amounts of ectopic wing vein material. This
phenotype is much more severe with ras1
R68Q however, which
frequentlyalsoresults inwing blisters.Panels (A) and(B) are included
for comparison only and are the same images shown in Figure 5.
(TIF)
Figure S4 Overexpression of ras1 in the eye induces
developmental defects. Both overgrowth and cell death
phenotypes are observed when Ras is overexpressed in the fly eye.
Flies overexpressing wildtype ras1 (B,G) exhibit relatively minor
d i s r u p t i o n si ne y ep a t t e r n i n ga n di nt h ec a s eo fsev-Gal4 driven
expression, a smallbut significant amount of overgrowth occursin the
anterior part of the eye (G). In contrast, overexpression of ras1
R68Q
with GMR-Gal4 (C-F) causes severe overgrowth and patterning
disruptions. An example from each of four independent transgenic
lines is shown to illustrate the range of phenotypes. Likewise,
overexpression of ras1
R68Q with sev-Gal4 elicits a much more
pronounced overgrowth phenotype in the anterior part of the eye
(H) compared to that of wildtype ras1 (G).Genotypes:(A) GMR-Gal4/
+,( B )GMR-Gal4/+;UAS-ras1/+,( C - F )GMR-Gal4/+;UAS-ras1
R68Q/
+,( G )sev-Gal4/+;UAS-ras1/+,( H )sev-Gal4/+;UAS-ras1
R68Q/+.
(TIF)
Table S1 GMR-rpr modifiers: Summary of genetic
interactions. Complementation groups are named for the known
gene to which they correspond. The group named ‘‘other’’ consists
of mutants that could not be placed into complementation groups.
-th-st- indicates that the mutation was roughly mapped by meiotic
recombination around the markers th and st and may be located on
either side, whereas sr-e indicates that the mutation maps between sr
and e. Alleles with the same map position and similar phenotypes
are grouped together for simplicity. Rep, reduced eye pigmentation;
Sup, suppressor; Enh, enhancer; —, no effect; ND, not done.
(TIF)
Table S2 GMR-hid suppressors: Summary of genetic
interactions. Legend is as described in Table S1. -th-st-,- cu-a n d
-sr- indicate that the mutation was roughly mapped by meiotic
recombination around the designated markers and may be located
on either side, whereas st-cu, cu-sr and sr-e indicate that the mutation
maps between the designated markers. The mutation characterized
in this study, Su(21-3s), is highlighted in yellow. Rep, reduced eye
pigmentation; Ro, rough eye; Wv, extra wing veins; Wk, weak; Sup,
suppressor; Enh, enhancer; -, no effect; ND, not done.
(TIF)
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